Yield10 Bioscience

Yield10 Bioscience Announces First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 15, 2024
Patent, Investment, Yield10 Bioscience, Farmer, Exercise, Bank statement, Sale, Carbon, Engineering, Michigan State University, Photosynthesis, RNA, Research, UPL, Biofuel, Plant

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024.
  • "Yield10 is a leader in the development of Camelina as a commercial crop and in engineering novel traits into the crop.
  • Recent progress by Yield10 is underscored by corporate milestones achieved since the start of 2024.
  • The decreased expenses quarter over quarter reflect the Company's efforts to better align its expenses with its cash resources.

Yield10 Bioscience Announces Delisting from Nasdaq

Retrieved on: 
星期三, 五月 15, 2024
Staff, Yield10 Bioscience, OTC Markets Group, Failure, Cryptocurrency

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq.

Key Points: 
  • WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq.
  • The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000.
  • Following the Nasdaq delisting, shares of the Company's common stock will continue to trade publicly.
  • This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a Staff delisting determination.

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期一, 四月 1, 2024
Research, USDA, Gene, Canadian Food Inspection Agency, Farmer, Grain, Tax, Webcast, BRS, PNT, Sale, Aviation, Biofuel, Yield10 Bioscience, Carbon, Genome, Michigan State University, EPA, Investment, RSR, Vision, DOE

WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update
    WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • During the fourth quarter of 2023, research and development expense increased by $0.1 million from $1.9 million in the fourth quarter of 2022 to $2.0 million.
  • General and administrative expenses decreased by $0.1 million to $1.3 million during the fourth quarter of 2023, from $1.4 million during the fourth quarter of 2022.
  • Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss the fourth quarter and full year 2023 results.

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

Retrieved on: 
星期四, 三月 28, 2024
Yield10 Bioscience, Interest

WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.

Key Points: 
  • WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.
  • Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m.
  • ET to review financial results, share corporate highlights, and provide an overall business update.
  • A replay of the call will be available approximately three hours after the end of the call through Monday, April 15, 2024.

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Retrieved on: 
星期二, 三月 26, 2024
Canadian Food Inspection Agency, PNT, Yield10 Bioscience, Genome, Fishery, CFR, Livestock, Ministry, Genetically modified organism, Agriculture

E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.

Key Points: 
  • E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.
  • In addition to the recent regulatory determination in Canada, the Company has previously received favorable regulatory determinations for planting E3902 Camelina in the United States, Argentina, and Chile.
  • United States: In 2018, the U.S. Department of Agriculture determined that E3902 Camelina is not considered regulated under 7 CFR part 340.
  • 1523 of 2001, and its amendments regarding GMOs confirming that this line is not considered regulated in Chile and can be cultivated like conventional Camelina.

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

Retrieved on: 
星期四, 三月 21, 2024
USDA, DHA, Oil, Eicosapentaenoic acid, Rothamsted, Partnership, BRS, Sale, Weed control, Salmon, Yield10 Bioscience, EPA, CFR, RSR, Dicarboxylic acid, Genetic engineering, Dietary supplement

WOBURN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s Camelina sativa ("Camelina”) varieties developed using genetic engineering (modified Camelina) to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States. The global markets for omega-3 fatty acids include aquafeed used for salmon and trout farming, pet feed, baby formula, nutraceutical and pharmaceutical products. Most omega-3 fatty acids are produced from ocean-caught fish. Production constraints and supply volatility of traditional fish oil sources are creating gaps in supply and driving the growing demand for new sources of omega-3. Utilizing Camelina as a land-based production platform has the potential to provide a new, reliable supply for omega-3 fatty acids. Yield10’s submissions along with the USDA-APHIS BRS responses are posted on the USDA’s website.

Key Points: 
  • Utilizing Camelina as a land-based production platform has the potential to provide a new, reliable supply for omega-3 fatty acids.
  • An RSR filed in July 2023 covers Camelina engineered to produce eicosapentaenoic acid (“EPA”) where the engineered omega-3 Camelina produces oil containing approximately 16-20% EPA.
  • In 2020, Yield10 signed a collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina.
  • Yield10 is also engineering second generation omega-3 Camelina lines with herbicide tolerance traits to enable weed control in large-scale commercial planting of the crop.

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

Retrieved on: 
星期四, 二月 29, 2024
Weed control, Soil, Yield10 Bioscience, Plant, IMI, Lead, Group 2, Herbicide, USDA, Agriculture

Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.

Key Points: 
  • Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.
  • Preliminary interim results of these field tests indicated that Yield10’s stacked HT winter Camelina performed well on the field plots pre-treated with Group 2 herbicides.
  • The winter Camelina was planted, and the field plots were subsequently sprayed with glufosinate in accordance with the field trial design.
  • Winter Camelina engineered with glufosinate tolerance remained healthy, while field plots of Camelina without the herbicide tolerance trait did not survive the spray.

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

Retrieved on: 
星期三, 二月 14, 2024
Soil, Aquaculture, Aviation, Yield10 Bioscience, Farmer, Rotation, Carbon, Vision, Biofuel, USDA, Partnership, Agriculture

and LONGMONT, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, and VISION Bioenergy Oilseeds , LLC (“VISION”), a U.S. agricultural company focused on commercial production of ultra-low carbon biofuel feedstock, today announced that Yield10 has granted to VISION a global license to certain proprietary varieties of Camelina sativa (“Camelina”) for the production of feedstock oil for biofuels.

Key Points: 
  • and LONGMONT, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, and VISION Bioenergy Oilseeds , LLC (“VISION”), a U.S. agricultural company focused on commercial production of ultra-low carbon biofuel feedstock, today announced that Yield10 has granted to VISION a global license to certain proprietary varieties of Camelina sativa (“Camelina”) for the production of feedstock oil for biofuels.
  • By facilitating the large-scale commercial production of herbicide tolerant Camelina, this license agreement is intended to empower farmers to capitalize on the growing biofuel market while advancing the decarbonization goals of aviation, maritime, and heavy-duty transport industries.
  • Commercial production of Camelina is currently ramping up in North America as a source of ultra-low carbon feedstock oil for the biofuel industry.
  • In consideration for the license and completion of certain deliverables, VISION will make cash payments to Yield10 totaling $3 million.

Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

Retrieved on: 
星期三, 二月 7, 2024
Partnership, USDA, Hearing, Growth, RSR, DHA, Oil, Eicosapentaenoic acid, Food, Yield10 Bioscience, EPA, Panel, Dietary supplement

WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today provided an update on its Omega-3 Camelina program. The Company has taken the strategic decision to prioritize in 2024 the execution of activities intended to accelerate and advance the Omega-3 Camelina program toward commercialization. Yield10 also reported that it has completed contra season production in Chile of Omega-3 EPA8 Camelina, which produces the eicosapentaenoic acid (“EPA”) component of the omega-3 oil found in fish.

Key Points: 
  • WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today provided an update on its Omega-3 Camelina program.
  • “In 2023, we achieved significant milestones in our omega-3 Camelina program scaling up EPA8 Camelina seed production and executing against our regulatory plan.
  • The Company is also transferring the EPA trait into proprietary Yield10 herbicide tolerant Camelina germplasm to boost in-field agronomics and yield.
  • In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina.

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Retrieved on: 
星期一, 一月 8, 2024
Sustainability, Eicosapentaenoic acid, Yield10 Bioscience, Consistency, Diet, Oil, RSR, DHA, Dicarboxylic acid, Salmon, EPA, Rothamsted, Dietary supplement

In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina.

Key Points: 
  • In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina.
  • Yield10 prioritized development and scale-up of EPA omega-3 Camelina and filed an RSR for approval of this line for production in the United States with USDA-APHIS in 2023.
  • Following immediately behind the EPA Camelina, Yield10 is scaling up an omega-3 Camelina line to produce oil containing both EPA and DHA fatty acids.
  • Furthermore, published human clinical studies have shown this oil to be an effective alternative to fish oil in the human diet.